AWM: Very Low Calorie Diets (2007)
To complete 5-year follow-up of an intensive weight loss program in established type 2 diabetic subjects.
- BMI > 30
- Type 2 diabetes
None specifically mentioned - published in prior article.
Recruitment
Recruited from hospital clinics and general practice.
Design
Cohort Study.
Blinding used (if applicable)
Not applicable.
Intervention (if applicable)
Group 1 selected VLCD for 6 weeks (650 kcal/day), Group 2 selected LCD and exercise, and 15 followed neither program. Group sessions of 8 - 15 subjects continued weekly for 6 months then monthly for 12 months.
Statistical Analysis
Results within wach group were analyzed by paired t test and for serum triglyceride levels and psychological well-being by Wilcoxon two sample rank tests.
Timing of Measurements
Body weight, waist/hip ratio, blood pressure, serum biochemistry, and psychological well being questionnaire results at baseline, 3, 6, 12, 36 and 60 months. Annual measurements of quality of life, BMI, waist/hip ratio, blood pressure, fasting blood glucose, serum fructosamine and serum lipids.
Dependent Variables
- Quality of life assessed by Psychological General Well-Being scale
- BMI
- Waist hip ratio
- Blood pressure
- Blood samples for blood glucose, serum fructosamine and serum lipids
Independent Variables
-
Group 1 selected VLCD for 6 weeks (650 kcal/day), Group 2 selected LCD and exercise, and 15 followed neither program. Group sessions of 8 - 15 subjects continued weekly for 6 months then monthly for 12 months.
Control Variables
Initial N: 45 subjects, 15 on VLCD, 15 on LCD and 15 on neither program
Attrition (final N): 13 on VLCD completed, 12 on LCD completed
Age: not mentioned
Ethnicity: not mentioned
Other relevant demographics:
Anthropometrics: not described in this article
Location: United Kingdom
VLCD Baseline |
VLCD 5 Years |
LCD Baseline |
LCD 5 Years |
|
BMI | 37.7 +/- 9.9 | 36.1 +/- 10.7 |
35.9 +/- 5.4 |
32.7 +/- 3.8 |
Waist (cm) |
117 +/- 24 |
114 +/- 20 |
113 +/- 13 |
108 +/- 4 |
SBP (mm Hg) | 139 +/- 17 | 143 +/- 13 | 142 +/- 22 | 130 +/- 20 |
DBP (mm Hg) | 76 +/- 10 | 77 +/- 11 | 85 +/- 13 | 74 +/- 13 |
Glucose (mmol/l) | 12 +/- 5 | 13 +/- 5 | 13 +/- 5 | 14 +/- 4 |
Fructosamine (umol/l) | 352 +/- 84 | 348 +/- 59 | 385 +/- 98 | 357 +/- 88 |
Cholesterol (mmol/l) | 6.8 +/- 1.2 | 5.7 +/- 1.3 | 5.9 +/- 1.3 | 5.3 +/- 1.5 |
Triglyceride (mmol/l) | 3.9 +/- 3.4 | 2.9 +/- 2.3 | 2.4 +/- 1.3 | 2.5 +/- 1.5 |
HDL Cholesterol (mmol/l) | 1.20 +/- 0.39 | 1.26 +/- 0.47 | 1.10 +/- 0.32 | 1.78 +/- 0.26 |
LDL Cholesterol (mmol/l) |
3.85 +/- 1.57 |
3.42 +/- 1.38 |
3.83 +/- 0.73 |
3.25 +/- 0.65 |
Other Findings
Weight loss was slower in the intensive conventional diet group than in the VLCD group, but better maintained at 5 years: group 1, 4.8 +/- 6 kg, group 2, 8.9 +/- 4 kg.
In the intensive conventional diet group, 5 year HDL cholesterol was increased by 1.78 +/- 0.26 mmol/l vs 1.10 +/- 0.32 mmol/l at baseline, and DBP reduced 74.5 +/- 13.3 vs 85.5 +/- 13.3 at baseline, both P < 0.05.
In this selected group of patients with type 2 diabetes (group 1 and 2), those successful with VLCD were able to safely achieve substantial weight loss for more than a year, which could allow major surgery to be carried out more safely. Those prepared to follow group sessions of diet and exercise for a longer term were able to sustain substantial weight loss at 5 years (>8 kg) but not a remission in their diabetes. This result may help in advising obese type 2 diabetic subjects on long and short-term success of these 2 strategies for weight loss.
University/Hospital: | Torbay Hospital Special Medical Grant Fund | ||
Not-for-profit |
|
Methods for collecting data not described. Subjects not well described. Small numbers of subjects in groups.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | ??? | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | ??? | |
2.2. | Were criteria applied equally to all study groups? | ??? | |
2.3. | Were health, demographics, and other characteristics of subjects described? | ??? | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
3. | Were study groups comparable? | ??? | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | ??? | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | ??? | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | ??? | |
4.1. | Were follow-up methods described and the same for all groups? | ??? | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | ??? | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | ??? | |
4.4. | Were reasons for withdrawals similar across groups? | ??? | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | Yes | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | Yes | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | Yes | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | Yes | |
6.6. | Were extra or unplanned treatments described? | Yes | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | No | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |